COMP <GO>
BAX vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Baxter International Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BAX 2
— ABBV 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ABBV
LAST: $23.50 (-7.70%) • MKT CAP: $12.15B
balance-sheet
2.22
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BAX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BAX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.10% | 70.20% | -40.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.40% | 29.00% | -31.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.79% | 3.47% | -0.68 | ABBV | /fcf-yield <GO> |
| Operating Margin | -2.70% | 24.60% | -27.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -8.50% | 6.90% | -15.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 8.60% | -2.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.86% | 2.27% | +0.59 | BAX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.22 | 5.33 | -3.11 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.3 | 65.1 | -22.80 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.15 | -0.20 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 113.1x | -95.10 | BAX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.15B | $513.86B | -$501.71B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BAX REV | ABBV REV | BAX GROSS % | ABBV GROSS % | BAX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.24B | $61.16B | 30.1% | 70.2% | $339.0M | $17.82B |
| FY 2024 | $10.64B | $56.33B | 37.5% | 70.0% | $540.4M | $17.83B |
| FY 2023 | $10.36B | $54.32B | — | — | $1.26B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BAX // BETA 0.95
ABBV // BETA 1.15